Free tool
FAERS Monitor: Atacand Hct
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021093 or its brand name (Atacand Hct, Candesartan Cilexetil, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.
Reports
2,609
Serious
2,165
83% of reports
Hospitalization
1,250
Death reported
170
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective311
- blood pressure increased239
- hypertension224
- dizziness196
- dyspnoea132
- fatigue126
- nausea124
- headache120
- drug dose omission107
- fall106
- malaise103
- off label use101
- vomiting99
- hypotension97
- asthenia90
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 45 |
| 2006 | 65 |
| 2007 | 89 |
| 2008 | 103 |
| 2009 | 139 |
| 2010 | 152 |
| 2011 | 376 |
| 2012 | 525 |
| 2013 | 170 |
| 2014 | 127 |
| 2015 | 126 |
| 2016 | 67 |
| 2017 | 54 |
| 2018 | 74 |
| 2019 | 95 |
| 2020 | 83 |
| 2021 | 81 |
| 2022 | 53 |
| 2023 | 34 |
| 2024 | 62 |
| 2025 | 41 |
| 2026 | 28 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,550 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood pressure increasedSignal | 239 | 12.6 | 11.2 | 2,560 |
| hypertensionSignal | 224 | 8.5 | 7.5 | 1,496 |
| drug dose omissionSignal | 107 | 5.2 | 4.3 | 364 |
| hypotensionSignal | 97 | 3.9 | 3.2 | 208 |
| dizzinessSignal | 196 | 3.2 | 2.8 | 296 |
| fallSignal | 106 | 2.6 | 2.1 | 102 |
| asthenia | 90 | 1.9 | 1.6 | 40 |
| drug ineffective | 311 | 1.9 | 1.7 | 141 |
| malaise | 103 | 1.9 | 1.6 | 43 |
| dyspnoea | 132 | 1.9 | 1.6 | 55 |
| vomiting | 99 | 1.7 | 1.4 | 28 |
| headache | 120 | 1.5 | 1.3 | 23 |
| fatigue | 126 | 1.3 | 1.1 | 9 |
| nausea | 124 | 1.3 | 1.1 | 7 |
| off label use | 101 | 0.9 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.